Siyuan Cheng

This study identifies INSM1 as a key regulator of neuroendocrine plasticity and tumor progression in prostate cancer, showing its role in lineage programs and identifying HHT as a potential therapeutic agent.

This study identifies March5 as a muscle proteostatic checkpoint that limits ATF4-dependent GDF15 production, linking muscle health to feeding and body composition.

The paper identifies RUNX1T1 as a marker of lineage plasticity across cancers and shows that targeting the RUNX1T1-HDAC complex can suppress plastic cell growth.

This study identifies Notch signaling as a graded rheostat regulating lineage plasticity and therapy resistance in prostate cancer, showing that intermediate Notch activity maintains stem-like progenitor states and that modulating Notch levels can restore drug sensitivity.

SCAPE provides an AI-driven platform for comprehensive single-cell data analysis, demonstrating its utility in lung cancer progression studies.

This study identifies Notch signaling as a driver of lineage plasticity and therapeutic resistance in enzalutamide-resistant prostate cancer and shows its inhibition reverses resistance in vitro.

This study identifies TET2 activation in slow-cycling cells as a driver of prostate cancer progression through epigenetic changes and shows targeting TET2 suppresses tumor growth.

This study investigates Wnt/beta-Catenin signaling in neuroendocrine prostate cancer, finding elevated pathway activity and potential therapeutic targeting.

This study investigates AR-driven gene expression and epigenetic changes in prostate cancer using multi-omics data from LNCaP cells, identifying gene expression shifts and AR binding patterns under androgen deprivation therapy.

This study identifies α-synuclein's role in regulating inflammatory gene expression in melanoma cells through RNA sequencing and validation.

This study examines PKM1 and PKM2 expression in mouse and human prostatic tissues across development, benign, and cancerous states, revealing distinct patterns in PCa and NEPCa.

This study shows ZNF397 loss leads to TET2-driven epigenetic changes, lineage plasticity, and resistance to AR-targeted therapies in AR-dependent cancers, with TET2 inhibitors reversing resistance.

PCTA provides a curated pan-cancer cell line transcriptome atlas with user-friendly tools for gene expression analysis across diverse cancer types.